CLINICAL_TRIALS
trial_result
· 2024-02-29
Clinical Trial Update: Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) [Phase 3]
Summary
Phase 3 trial update for ARCADE evaluating angiotensin II receptor blockade in vascular Ehlers-Danlos syndrome has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Ehlers-Danlos Syndrome, Vascular Type | Phase 3 | Status: COMPLETED